ARWR begins dosing ARO-HBV | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left) 5-yrs @ $199 (only 30 left) 2-yrs @ $99 (only 27 left)

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34225 of 34949  at  3/27/2018 1:49:26 PM  by

egomaniakos


 In response to msg 34223 by  stencil
view thread

Re: ARWR begins dosing ARO-HBV

One would have to be frankly moronic to believe a Jefferies "research report".

The only thing objectively first in class is Anzalone's ability to constantly raise money despite burning investors on poorly planned research development, for the company and himself.

Jefferies is simply completing the deal. They got the last secondary and made the commission. Anzalone got 500K of shares priced at 0. The buyers that Jefferies lined up now get the opportunity to sell their shares at a guaranteed profit.

Jefferies, on 0 data on TRIM is no more educated on whether TRIM is the new best in class than a punter betting on a novice horse never seen before.

What is definitely not a coincidence is that Jefferies happened to have an independent report ready for release on the day ARWR announced first dosing in a safety P1! Wow it seems a leader in safety to me. Especially with the track record the company has.

ego





     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 342
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
34226 Re: ARWR begins dosing ARO-HBV stencil 0 3/27/2018 2:11:02 PM






Financial Market Data provided by
.


Loading...